Digital Day Two
All Times in EST
9:00 am Chair’s Opening Remarks
Formulating & Manufacturing Bacteriophages for Commercial Use
9:10 am Quality-By-Design Led Approaches for Manufacturing & Formulation of Phage Therapeutics
- Danish Malik Reader in Industrial Biotechnology , Loughborough University
- Benefits of using on-line and at-line process analytics for better process monitoring, process optimization and control
- Utilizing nanoparticle characterization tools coupled with design-of experiments methodology to optimize liquid formulations
- Mapping QbD elements for phage manufacture focusing on Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs) of the
drug substance, and identifying Critical Process Parameters (CPPs) that link to CQAs
9:30 am Phages for Faces: Chemical-Free Solutions for the Cosmetics Industry
- Natalie Ma Head of Business Development, Felix Biotechnology
- Sharing our understanding of the skin microbiome and its relationship to how beauty and skin health is beginning to show that a one size fits all solution is
- Understanding why phages are the most targeted and safest tools available to address challenging bacteria
- Looking for safer and more friendly solutions to manage cosmetic challenges – the time is right for phage
9:50 am Deep Dive into the Characteristics of Phages to Exploit Their Host-Toxic Properties
- Mikael Skurnik Professor – Bacteriology , University of Helsinki
- Exploitation of the dark matter in phage genomes to find novel targets to develop new antibiotics
- Phages have evolved to control and take over the metabolism of its host bacterium including the use of gene products that are directly toxic
- Screening phage genomes for toxic phage proteins to use them for target identification
10:10 am Speaker Q&A
10:40 am Virtual Speed Networking
This session is the ideal opportunity to take advantage of informal networking time, and understand who is also prioritising and overcoming challenges within the various sectors of the bacteriophage world
11:10 am Morning Break & Networking
Leveraging Clinical Trial Successes & Pitfalls for Triumphant Phage Therapies
11:30 am Streamlining Microbiology Testing for the Treatment of Antibiotic Resistant Urinary Tract Infections
- Melissa Haines NIHR Academic Clinical Lecturer in Infectious Diseases and Medical Microbiology , University Hospitals of Leicester NHS Trust - University of Leicester
- The NHS Plan & gram-negative sepsis
- Antibiotic resistant urinary tract infection
- Phage selection techniques for phage cocktails
11:50 am Can Phages Improve the Management of Prosthetic Joint Infections?
- Hesham Abdelbary Orthopedic Surgeon , The Ottawa Hospital Research Institute
- Burden of PJI disease, disease pathogenesis and therapeutic challenges
- The unique therapeutic value of phages in managing PJI
- Importance of designing clinically representative in vivo models to assess efficacy of phages
12:10 pm Speaker Q&A
12:30 pm Lunch & Networking
Integrating Lessons From Compassionate Use to Real Product Development
1:30 pm Development of Cocktails for Personalized Therapeutic Use
- Sabrina Green Director of Research & Development , Baylor - TAILΦR Service Center
- Understanding the biological environment and the need to develop phages tailored for these niches
- Learning from and improving our therapeutic cocktails based on data from our own patient cases.
- Accelerating the development of phage cocktails for personalized phage therapy
1:50 pm Can the Compassionate Use of Bacteriophages Ultimately Become Accessible Commercially?
- Zemphira Alavidze Medical Microbiologist, Phage Therapy Center
- The use of bacteriophages in Georgia
- Our clinical experience and application of phages
- Presentation of some of our case histories
2:10 pm Phage Therapy in Implantable Devices: The Mayo Clinic Experience
- Gina Suh Assistant Professor, Mayo Clinic
- The considerations taken when selecting patients for phage therapy
- Discussing the factors that may have impacted a patient’s individual response to phage therapy
- How can compassionate use cases inform clinical trials?
2:30 pm Speaker Q&A
3:00 pm Afternoon Break & Networking
Using Technology to Eliminate Pathogenic Bacteria in any Industry & Environment
3:30 pm Predicting a Phage’s Host-Range from Genomic Data
- Dr. Iddo Weiner Director, Head of Software, BiomX
- Phages are highly specific, often infecting only specific strains within a bacterial species
- Phage infection is a multifactorial trait, based on a variety of characteristics in both phage and host genomes
- We have made significant progress in deciphering some of these genomic features, which enables us to predict the interaction between a phage and its potential hosts
3:50 pm Building a Universal Phage Selection Platform by Applying Recent NLP Breakthroughs to Genomic Data of Phages & Bacteria
- Chris Lis Co-Founder & Chief Technology Officer , Uniphage
- Why treat genomes like natural languages? How can we create genomic language models based on Transformers, models that revolutionized the natural language processing (NLP) field?
- How can we use genomic language models to select the best therapeutic phages against any pathogen of interest?
- What is the future of transformer-powered genomics and phage therapeutics?
4:10 pm Requirements for an In-Vitro Diagnostic to Determine the Phage a Patient Needs on a Routine Basis
- Bob Blasdel Research Director , Vésale Bioscience
- What are the core challenges of diagnosing phage sensitivity?
- What is the actual biological property of phage activity that we would ideally want to detect?
- What are the requirements of a clinical microbiology laboratory to routinely implement a diagnostic?